Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 3/20 | 0.39 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.36 |
| ▸ | FEN1 | P39748 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 4/20 | 0.35 |
| ▸ | PLK4 | O00444 | 1/20 | 0.34 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30456972 | 0.74 | AXL (0.39) | ADORA2AADORA1CDK8AXLPIK3CA | |
| SCHEMBL1564616 | 0.74 | AXL (0.39) | ADORA2AADORA1CDK8AXLPIK3CA | |
| SCHEMBL20674174 | 0.74 | RIPK1 (0.44) | CDK8AXLPIK3CAPIK3CDPIK3CB | |
| SCHEMBL17388984 | 0.74 | CDK8 (0.39) | CDK8AXLPIK3CAPIK3CDPIK3CB | |
| SCHEMBL15930207 | 0.74 | CDK8 (0.36) | CDK8AXLPIK3CAPIK3CDPIK3CB | |
| SCHEMBL21958557 | 0.74 | KDR (0.36) | CDK8AXLPIK3CAPIK3CDPIK3CB | |
| SCHEMBL30062504 | 0.74 | KDR (0.36) | CDK8AXLPIK3CAPIK3CDPIK3CB | |
| SCHEMBL18238981 | 0.74 | CDK8 (0.37) | CDK8AXLPIK3CAPIK3CDPIK3CB | |
| SCHEMBL19153634 | 0.72 | ADORA2A (0.56) | ADORA2AADORA1AXL | |
| SCHEMBL26538899 | 0.71 | FGFR1 (0.38) | CDK8AXLPIK3CAPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| US-11230544-B1 | Substituted 1,3,4-thiadiazoles as GLS1 inhibitors | MEDSHINE DISCOVERY INC. (CN) | 2022-01-25 | — | — | US | disclosed |
| WO-2021194914-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-09-30 | — | — | WO | disclosed |
| EP-2951169-B1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-28 | — | — | EP | disclosed |
| US-20170327514-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-16 | — | — | US | disclosed |
| US-9732093-B2 | FLAP modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-15 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20150368270-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-24 | — | — | US | disclosed |
| US-20150252008-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-10 | — | — | US | disclosed |
| US-9073876-B2 | Flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-07 | — | — | US | disclosed |
| US-20140221310-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (US) | 2014-08-07 | — | — | US | disclosed |
| US-20070203209-A1 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203209-A1 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| WO-2007022501-A2 | USEFUL INDOLE COMPOUNDS | MICROBIA, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | ADORA2A 4582/4885ADORA1 4484/4885CDK8 881/4885 |
| US-20170327514-A1 | FLAP MODULATORS | FEN1, PGF, TBXA2R | ADORA2A 39/4885ADORA1 50/4885CDK8 1875/4885 |
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | DDX21, HRAS, RPL17 | ADORA2A 4573/4885ADORA1 4623/4885CDK8 871/4885 |
| US-20140221310-A1 | FLAP MODULATORS | FEN1, PGF, PTGIS | ADORA2A 38/4885ADORA1 53/4885CDK8 1708/4885 |
| US-20150368270-A1 | FLAP MODULATORS | FEN1, PGF, TBXA2R | ADORA2A 39/4885ADORA1 50/4885CDK8 1875/4885 |
| US-11230544-B1 | Substituted 1,3,4-thiadiazoles as GLS1 inhibitors | GLS2, GLS, GYS2 | ADORA2A 2651/4885ADORA1 1805/4885CDK8 473/4885 |
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | ADORA2A 3658/4885ADORA1 4282/4885CDK8 1753/4885 |
| US-20070203209-A1 | Useful indole compounds | TPH2, HRH2, HRH1 | ADORA2A 263/4885ADORA1 498/4885CDK8 1185/4885 |
| US-20150252008-A1 | FLAP MODULATORS | FEN1, PGF, PTGIS | ADORA2A 38/4885ADORA1 53/4885CDK8 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.